Arog Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 20
- Market Cap
- -
- Website
- http://www.arogpharma.com
Clinical Trials
23
Active:6
Completed:10
Trial Phases
3 Phases
Phase 1:10
Phase 2:9
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
Phase 1
10 (45.5%)Phase 2
9 (40.9%)Phase 3
3 (13.6%)Individual Patient Compassionate Use of Crenolanib
- Conditions
- FLT3-ITD MutationFLT3/TKD MutationPDGFR-Alpha D842VPDGFRA Gene Amplification
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Registration Number
- NCT03620318
- Locations
- 🇮🇹
Ospedale Policlinico San Martino, Genova, Italy
A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia
Phase 2
Withdrawn
- Conditions
- Relapsed/Refractory FLT3-mutated AML
- Interventions
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Registration Number
- NCT03324243
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Phase 3
Recruiting
- Conditions
- Newly Diagnosed FLT3 Mutated AML
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT03258931
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸US Davis Health, Sacramento, California, United States
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
Phase 3
Recruiting
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT03250338
- Locations
- 🇺🇸
City of Hope National Medical Center, Sacramento, California, United States
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
Phase 1
Completed
- Conditions
- Esophagogastric Adenocarcinoma
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03193918
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found